# Neoadjuvant T-VEC in High Risk Early Melanoma

> **NCT04427306** · PHASE2 · SUSPENDED · sponsor: **University of California, Davis** · enrollment: 6 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** T-Vec

## Key facts

- **NCT ID:** NCT04427306
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-05-21
- **Primary completion:** 2022-06-27
- **Final completion:** 2024-05-21
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** low enrollment
- **Last updated:** 2023-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04427306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04427306, "Neoadjuvant T-VEC in High Risk Early Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04427306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*